We are live on
!
Find out more
GA
Geneva Advisors Portfolio holdings
AUM
$5.81B
Turnover
22.5%
1-Year Est. Return
23.71%
This Fund
S&P 500
This Quarter
Est. Return
-6.12%
1 Year Est. Return
+23.71%
3 Year Est. Return
+53.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.96B
AUM Growth
-$641M
(-11%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
23.33%
Holding
765
New
46
Increased
242
Reduced
270
Closed
98
Avg Time Held
1.5
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Manhattan Associates
MANH
|
+$33.6M |
| 2 |
Amazon
AMZN
|
+$32.3M |
| 3 |
CEB
CEB Inc.
CEB
|
+$27.7M |
| 4 |
Gilead Sciences
GILD
|
+$27.3M |
| 5 |
Merck
MRK
|
+$25.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$49.9M |
| 2 |
TWX
Time Warner Inc
TWX
|
+$30.5M |
| 3 |
Stericycle Inc
SRCL
|
+$29.3M |
| 4 |
Macquarie Infrastructure Holdings, LLC
MIC
|
+$25M |
| 5 |
Sunoco
SUN
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.16% |
| 2 | Financials | 16.84% |
| 3 | Consumer Discretionary | 14.26% |
| 4 | Technology | 13.32% |
| 5 | Industrials | 10.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
DELISTED
Dominion Energy Midstream Ptr LP
DM
| $4.06M | 0.08% |
151,115
-7,665
| -5% | -$258K |
2014 Q4
3 quarters
|
|
127
AT&T
T
$161B
| $3.94M | 0.08% |
159,905
+32,474
| +25% | +$828K |
2013 Q2
9 quarters
|
|
128
Criteo S.A.
CRTO
$772M
| $3.85M | 0.08% |
102,454
+14,033
| +16% | +$642K |
2015 Q1
2 quarters
|
|
129
AerCap
AER
$22.9B
| $3.85M | 0.08% |
100,560
-4,920
| -5% | -$217K |
2014 Q3
4 quarters
|
|
130
lululemon athletica
LULU
$11.5B
| $3.81M | 0.08% |
75,285
-11,470
| -13% | -$699K |
2013 Q3
8 quarters
|
|
131
DELISTED
Luxottica Group
LUX
| $3.72M | 0.08% |
53,700
-47,079
| -47% | -$3.26M |
2013 Q2
9 quarters
|
|
132
Canadian National Railway
CNI
$72.9B
| $3.67M | 0.07% |
64,720
+31,365
| +94% | +$1.83M |
2013 Q2
9 quarters
|
|
133
IBM
IBM
$221B
| $3.6M | 0.07% |
25,995
-405
| -2% | -$59.8K |
2013 Q2
9 quarters
|
|
134
Wells Fargo
WFC
$248B
| $3.56M | 0.07% |
69,364
+4,982
| +8% | +$274K |
2013 Q2
9 quarters
|
|
135
Abbott
ABT
$181B
| $3.56M | 0.07% |
88,418
-3,725
| -4% | -$176K |
2013 Q2
9 quarters
|
|
|
BWLD
136
DELISTED
Buffalo Wild Wings, Inc.
BWLD
| $3.53M | 0.07% |
18,270
+12,996
| +246% | +$2.44M |
2015 Q2
1 quarter
|
|
137
Bright Horizons
BFAM
$3.42B
| $3.5M | 0.07% |
54,560
+35,977
| +194% | +$2.22M |
2014 Q3
4 quarters
|
|
138
Qualcomm
QCOM
$191B
| $3.5M | 0.07% |
65,094
-18,397
| -22% | -$1.09M |
2013 Q2
9 quarters
|
|
139
Equinor
EQNR
$106B
| $3.42M | 0.07% |
234,864
-9,804
| -4% | -$155K |
2014 Q2
5 quarters
|
|
|
ESRX
140
DELISTED
Express Scripts Holding Company
ESRX
| $3.37M | 0.07% |
41,588
+7,540
| +22% | +$657K |
2013 Q2
9 quarters
|
|
141
RTX Corp
RTX
$252B
| $3.31M | 0.07% |
59,057
-2,839
| -5% | -$175K |
2013 Q2
9 quarters
|
|
142
Philip Morris
PM
$312B
| $3.29M | 0.07% |
41,515
+2,964
| +8% | +$244K |
2013 Q2
9 quarters
|
|
143
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
| $3.26M | 0.07% |
94,453
+55,764
| +144% | +$2.27M |
2014 Q3
4 quarters
|
|
144
Novo Nordisk
NVO
$173B
| $3.26M | 0.07% |
120,102
-6,268
| -5% | -$177K |
2014 Q2
5 quarters
|
|
|
IMPV
145
DELISTED
Imperva, Inc.
IMPV
| $3.26M | 0.07% |
49,748
+22,630
| +83% | +$1.5M |
2014 Q4
3 quarters
|
|
146
3M
MMM
$85.3B
| $3.2M | 0.06% |
26,973
-200
| -0.7% | -$24.6K |
2013 Q2
9 quarters
|
|
147
Accenture
ACN
$138B
| $3.11M | 0.06% |
31,612
-338
| -1% | -$33.5K |
2013 Q2
9 quarters
|
|
148
Aemetis
AMTX
$105M
| $3.1M | 0.06% |
1,128,730
+201,625
| +22% | +$657K |
2014 Q2
5 quarters
|
|
149
T. Rowe Price
TROW
$21.6B
| $3.09M | 0.06% |
44,446
+1,809
| +4% | +$134K |
2013 Q2
9 quarters
|
|
150
ASML
ASML
$637B
| $3.07M | 0.06% |
34,931
-9,589
| -22% | -$908K |
2014 Q1
6 quarters
|
|
Similar funds
CAM
DL
TCM
HCM
AL
AT
Geneva Advisors's Q3 2015 Portfolio in Review
As of Q3 2015, Geneva Advisors held 765 positions worth $4.96B, down 11% from $5.6B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geneva Advisors withdrew a net $193M in Q3 2015, closing 98 positions and reducing 270 holdings. Its most notable exit was Potash Corp Of Saskatchewan, an estimated $21.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Geneva Advisors opened a new position in Alphabet (Google) Class A worth $15.8M.
- Geneva Advisors's largest Q3 2015 buy was Alphabet (Google) Class A: 496,420 shares worth $15.8M.
- Geneva Advisors added most to Manhattan Associates in Q3 2015, an estimated $33.6M increase.
- Geneva Advisors's biggest Q3 2015 reduction was Biogen, cutting an estimated $49.9M.
- Geneva Advisors fully exited Potash Corp Of Saskatchewan in Q3 2015, selling an estimated $21.6M.
- Geneva Advisors's ten largest holdings make up 23% of its $4.96B portfolio in Q3 2015.
- Geneva Advisors opened 46 new positions and closed 98 in Q3 2015.
- Geneva Advisors's portfolio value fell 11% quarter-over-quarter to $4.96B.
Based on Geneva Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.